表紙
市場調查報告書

新型冠狀病毒感染疾病 (COVID-19) 診斷藥、治療藥的全球市場 (∼2025年):PCR檢驗、抗體檢驗、免疫治療藥、疫苗、抗病毒藥物、細胞治療藥、血漿治療藥

COVID-19 Diagnostics (PCR Testing, Antibody Testing) and Therapy (Immunotherapy, Vaccines, Antiviral, Cell-based, Plasma therapy) Market Opportunity Assessment and Global Forecast to 2025

出版商 Meticulous Market Research Pvt. Ltd. 商品編碼 946876
出版日期 內容資訊 英文 100 Pages
訂單完成後即時交付
價格
新型冠狀病毒感染疾病 (COVID-19) 診斷藥、治療藥的全球市場 (∼2025年):PCR檢驗、抗體檢驗、免疫治療藥、疫苗、抗病毒藥物、細胞治療藥、血漿治療藥 COVID-19 Diagnostics (PCR Testing, Antibody Testing) and Therapy (Immunotherapy, Vaccines, Antiviral, Cell-based, Plasma therapy) Market Opportunity Assessment and Global Forecast to 2025
出版日期: 2020年07月03日內容資訊: 英文 100 Pages
簡介

世界各國的衛生署及醫療研究人員,以新型冠狀病毒感染疾病 (COVID-19)的感染擴大防止為目標,競爭摸索著解決方案。開發中的治療藥的50%以上雖然依然在前臨床階段,但是由於FDA的緊急使用許可 (EUA) 等努力,預期R&D流程加速。預計COVID-19診斷藥、治療藥的市場機會,2025年達到139億美元的規模。其中疫苗及抗病毒藥物,全球的研究人員現在也最大量地研究。

本報告提供全球新型冠狀病毒感染疾病 (COVID-19) 診斷藥、治療藥的市場調查,市場定義和概要,COVID-19概要、現狀,COVID-19診斷藥、治療藥的開發平台趨勢,各地區的影響與開發的措施,主要企業的配合措施等彙整資料。

第1章 簡介

第2章 調查手法

第3章 冠狀病毒:流行病學

第4章 摘要整理

  • 簡介
  • 世界經濟的影響
  • COVID-19的應對
  • COVID-19:研究開發平台
  • COVID-19開發平台上的課題
  • 主要企業

第5章 Covid-19:醫療部門的影響

  • 簡介
  • 主要趨勢、詳細部門的影響
  • 診斷藥
    • PCR、迅速抗原檢驗、核酸為基礎的檢驗
    • 抗體檢驗、血清檢驗
  • 治療藥
    • 疫苗
    • 免疫療法(抗體)
    • 抗病毒藥物
    • 細胞為基礎的治療藥
    • 其他

第6章 影響分析:各地區

  • 簡介
  • 北美
  • 歐洲
  • 亞太地區
  • 其他地區

第7章 競爭情形

  • 簡介
  • 契約、交易、聯盟、合作、JV
  • R&D最新趨勢
  • 認證、核准
  • 捐獻
  • 投入資金
  • 生產能力的擴大
  • 其他成長策略

第8章 企業的最新趨勢

  • 企業區分
  • 診斷藥
    • Roche Holding Ag
    • Thermo Fisher Scientific, Inc.
    • Becton, Dickinson and Company
    • Abbott Laboratories
    • Cepheid (Subsidiary of Danaher Corporation)
  • 抗病毒藥物
    • Abbivie Corporation
    • Gilead Sciences, Inc.
    • Eli Lilly And Company
  • 疫苗開發
    • Moderna, Inc.
    • Novavax, Inc
    • Medicago, Inc
    • Inovio Pharmaceuticals, Inc.
    • GlaxoSmithKline (GSK)
    • Sanofi S.A.
    • Johnson & Johnson
  • 免疫治療
    • Sorrento Therapeutics, Inc.
    • Astrazeneca Plc
    • Pfizer, Inc.
    • Cti Biopharma Corporation
    • Oncoimmune, Inc.
  • 細胞治療
    • Athersys,Inc.
    • Cellularity,Inc.
    • Pluristem Therapeutics,Inc.
  • 血漿療法
    • Takeda Pharmaceutical Company Ltd
目錄

The healthcare systems have been struggling to manage the COVID-19 patient population globally and hence the medical researchers are racing to find a solution to the pandemic. According to this latest publication from Meticulous Research®, the leading areas of research include antibodies, protein-based vaccines, antiviral, drug repurposes, RNA-based vaccines, non-replicating viral vectors, and cell-based therapies. While more than 50% of the therapies being developed are in preclinical stage, government initiatives, such as Emergency Use Authorization (EUA) by FDA, is expected to accelerate the research and development (R&D) process.

Based on healthcare options, the COVID-19 impact assessment is analyzed into diagnostics and treatments areas. The market opportunity of these products is estimated to reach USD 13.9 billion in 2025. The diagnostics segment is further divided into PCR-based testing and antibody testing. The treatment area is segmented into vaccines, immunotherapies, anti-virals, cell-based therapies, and other therapies. Vaccines and anti-virals are the most explored treatment options currently being investigated by researchers worldwide.

Geographically, North America has been the most affected region, primarily attributed to the U.S. being the most affected country having most number of confirmed cases as well as deaths, globally. Other most affected nations include the U.K., Spain, France, Italy, Brazil, Germany, and India among others. Further, almost all the affected nations have experienced rapid economic decline leading GDP decline, increase in unemployment rates, and increase in the inflation rates. To overcome the situation, governments have imposed restriction on people movement as well as invested resources towards dealing with crisis and supporting all research and medical efforts towards developing a treatment option. The U.S., Canada, the U.K., Germany, China, and India are some of the key nations leading the research and production efforts geared towards developing COVID-19 medication.

Some of the key players engaged in COVID-19 diagnostics and treatment development include: Roche Holding AG (Switzerland), Thermo Fisher Scientific, Inc. (U.S.), Abbott Laboratories (U.S.), Becton, Dickinson and Company (U.S.), AbbVie Corporation (U.S.), Gilead Sciences, Inc. (U.S.), Eli Lilly and Company (U.S.), Moderna, Inc. (U.S.), Novavax, Inc. (U.S.), Medicago, Inc. (U.S.), Inovio Pharmaceuticals, Inc. (U.S.), GlaxoSmithKline (U.K.), Sanofi S.A. (France), Johnson & Johnson (U.S.), Sorrento Therapeutics, Inc. (U.S.), AstraZeneca Plc (U.K.), Pfizer, Inc. (U.S.), CTI Biopharma Corporation (U.S.), OncoImmune, Inc. (U.S.), Athersys, Inc. (U.S.), Celularity, Inc. (U.S.), Pluristem Therapeutics (Israel), and Takeda Pharmaceuticals Company Ltd (Japan), among others.

Scope of the Report:

COVID-19 Product Pipeline

  • Diagnosis
    • PCR Testing
    • Antibody Testing
  • Treatment
    • Vaccines
    • Immunotherapy
    • Antiviral
    • Cell-based Therapy
    • Other Therapies

COVID-19: Impact on Healthcare Industry

  • Diagnostics
    • Rapid Test Kits
    • PCR / Rapid Antigen Testing / Nucleic Acid-Based Tests
  • Advantages Offered by PCR Testing in COVID -19 Diagnosis
  • Restraints
  • Key Companies
    • Antibody Testing / Serological Testing
  • Advantages Over Molecular Tests
  • Use of Antibody Testing for Herd Immunity Analysis and Easing Lock-Down
  • Restraints
  • Key Companies
    • Therapies
  • Vaccines
  • Immunotherapies (Antibodies)
  • Monoclonal Antibody
  • T-Cell Therapy
  • Potential Game Changers: Antibodies
  • Ilaris (Canakinumab)
  • Sylvant (Siltuximab)
  • Lenzilumab
  • Ultomiris (Ravulizumab-Cwvz)
  • Tocilizumab
  • Anti-Virals
  • Potential Game Changers
  • Chloroquine and Hydroxychloroquine (HCQ)
  • Remdesivir
  • Cell-Based Therapies
  • Other Therapies
  • Plasma Therapy
  • Devices

COVID-19 Industry Impact Assessment, by Geography

  • North America
  • Europe
  • Asia-Pacific (APAC)
  • Rest of the World (RoW)

Table of Contents

1. Introduction

  • 1.1. Market Definition
  • 1.2. Markets Covered
  • 1.3. Years Considered for the Study
  • 1.4. Currency
  • 1.5. Key Stakeholders

2. Research Methodology

  • 2.1. Research Methodology Steps
  • 2.2. Secondary and Primary Research Methodology
    • 2.2.1. Secondary Research
      • 2.2.1.1. Key Data from Secondary Sources
    • 2.2.2. Primary Research
      • 2.2.2.1. Key Data from Primary Sources
      • 2.2.2.2. Key Insights from Primary Sources
  • 2.3. Market Size Estimation Methodology
  • 2.4. Market Forecast Methodology
  • 2.5. Market Breakdown and Data Triangulation

3. Coronavirus: Epidemiology

  • 3.1. About Coronavirus
  • 3.2. Transmission & Symptoms
  • 3.3. Prevention
  • 3.4. Epidemiology

4. Executive Summary

  • 4.1. Introduction
  • 4.2. Global Economic Impact
  • 4.3. COVID-19 Response
  • 4.4. COVID-19 Research Pipeline
  • 4.5. COVID-19 Pipeline Development Challenges
  • 4.6. Key Companies

5. Covid-19: Impact on Healthcare Industry

  • 5.1. Introduction
  • 5.2. Key Trends & Impact on Healthcare Subsegments
  • 5.3. Diagnostics
    • 5.3.1. PCR / Rapid Antigen Testing / Nucleic Acid-Based Tests
      • 5.3.1.1. Advantages Offered by PCR Testing in COVID -19 Diagnosis
      • 5.3.1.2. Restraints
      • 5.3.1.3. Key Companies
    • 5.3.2. Antibody Testing / Serological Testing
      • 5.3.2.1. Advantages Over Molecular Tests
      • 5.3.2.2. Use of Antibody Testing for Herd Immunity Analysis and Easing Lock-Down
      • 5.3.2.3. Restraints
      • 5.3.2.4. Key Companies
  • 5.4. Therapies
    • 5.4.1. Vaccines
    • 5.4.2. Immunotherapies (Antibodies)
      • 5.4.2.1. Monoclonal Antibody
      • 5.4.2.2. T-Cell Therapy
      • 5.4.2.3. Potential Game Changers: Antibodies
        • 5.4.2.3.1. Ilaris (Canakinumab)
        • 5.4.2.3.2. Sylvan (Siltuximab)
        • 5.4.2.3.3. Lenzilumab
        • 5.4.2.3.4. Ultomiris (Ravulizumab-CWVZ)
        • 5.4.2.3.5. Tocilizumab
    • 5.4.3. Antivirals
      • 5.4.3.1. Potential Game Changers
        • 5.4.3.1.1. Chloroquine and Hydroxychloroquine (HCQ)
        • 5.4.3.1.2. Remdesivir
    • 5.4.4. Cell-Based Therapies
    • 5.4.5. Other Therapies
      • 5.4.5.1. Plasma Therapy
      • 5.4.5.2. Devices

6. Geography Impact Assessment

  • 6.1. Introduction
    • 6.1.1. Global Virtual Fund-Raising Event to Raise USD 8 Billion for Coronavirus Vaccine
  • 6.2. North America
    • 6.2.1. COVID-19 Impact on the U.S. Economy
    • 6.2.2. Significant R&D Investment by the U.S. Government for COVID-19 Treatment
    • 6.2.3. High Dependence on the U.S. on Drugs Import Expected to Create Drug Shortages
    • 6.2.4. Investments by Coalition for Epidemic Preparedness Innovations (CEPI) and Canadian Government
    • 6.2.5. Canada Announced Investment of USD 192 Million on Vaccine Development as Well as Partnering with Industry and Academics
    • 6.2.6. Creation of SARS-COV2 Vaccine-Bank by Researchers in Canada
  • 6.3. Europe
    • 6.3.1. Economic Impact of COVID-19: European Nations
    • 6.3.2. European Firms to Lead the COVID-19 Treatment Researches
    • 6.3.3. U.K. at Forefront in Drug Development Researches to Fight Covid-19
    • 6.3.4. Partnership of European Pharmaceutical Giants - Sanofi and GSK To Develop COVID-19 Vaccine
    • 6.3.5. German Vaccine Became the First European MRNA Vaccine to Enter Human Testing
    • 6.3.6. Growing Interest of Billionaire in German Drug Development for COVID-19
  • 6.4. APAC
    • 6.4.1. Economic Impact of COVID-19: APAC
    • 6.4.2. Asian Countries Leading the Diagnostics Test Commercialization
    • 6.4.3. India In Favourable Position for Future Production Of COVID-19 Vaccine
    • 6.4.4. Chinese Lockdown to Negatively Impact the Drugs Supply Chain
  • 6.5. Rest of the World
    • 6.5.1. Government Initiatives to Support COVID-19 Medicine Research & Other Drug Supply in Brazil
    • 6.5.2. Saudi Arabia to Invest USD 2 Billion in Coronavirus Vaccine Development
    • 6.5.3. Government Initiatives to Support Rapid Development of COVID-19 Therapy in South Africa

7. Competitive Landscape

  • 7.1. Introduction
  • 7.2. Agreements/Deals/Partnerships/Collaborations/Joint Ventures
  • 7.3. R&D Updates
  • 7.4. Auhrozation / Approvals
  • 7.5. Donations Made
  • 7.6. Funding Received
  • 7.7. Capacity Expansion
  • 7.8. Other Growth Strategies

8. Company Updates

  • 8.1. Company Segmentation
  • 8.2. Diagnostic Companies
    • 8.2.1. Roche Holding Ag
      • 8.2.1.1. About the Firm
      • 8.2.1.2. COVID-19 Pipeline
      • 8.2.1.3. Recent Developments
    • 8.2.2. Thermo Fisher Scientific, Inc.
      • 8.2.2.1. About the Firm
      • 8.2.2.2. COVID-19 Pipeline
      • 8.2.2.3. Recent Developments
    • 8.2.3. Becton, Dickinson and Company
      • 8.2.3.1. About the Firm86
      • 8.2.3.2. COVID-19 Pipeline
      • 8.2.3.3. Recent Developments
    • 8.2.4. Abbott Laboratories
      • 8.2.4.1. About the Firm
      • 8.2.4.2. COVID-19 Pipeline
      • 8.2.4.3. Recent Developments
    • 8.2.5. Cepheid (Subsidiary of Danaher Corporation)
      • 8.2.5.1. About the Firm
      • 8.2.5.2. COVID-19 Pipeline
      • 8.2.5.3. Recent Developments
  • 8.3. Antivirals
    • 8.3.1. Abbivie Corporation
      • 8.3.1.1. About the Firm
      • 8.3.1.2. COVID-19 Pipeline
      • 8.3.1.3. Recent Developments
    • 8.3.2. Gilead Sciences, Inc.
      • 8.3.2.1. About the Firm
      • 8.3.2.2. Covid-19- Pipeline
      • 8.3.2.3. Recent Developments
    • 8.3.3. Eli Lilly And Company
      • 8.3.3.1. About the Firm
      • 8.3.3.2. Covid-19- Products
      • 8.3.3.3. Recent Developments
  • 8.4. Vaccine Developers
    • 8.4.1. Moderna, Inc.
      • 8.4.1.1. About the Firm
      • 8.4.1.2. COVID-19 Pipeline
      • 8.4.1.3. Recent Developments
    • 8.4.2. Novavax, Inc
      • 8.4.2.1. About the Firm
      • 8.4.2.2. COVID-19 Pipeline
      • 8.4.2.3. Recent Developments
    • 8.4.3. Medicago, Inc
      • 8.4.3.1. About the Firm
      • 8.4.3.2. COVID-19 Pipeline
      • 8.4.3.3. Recent Developments
    • 8.4.4. Inovio Pharmaceuticals, Inc.
      • 8.4.4.1. About the Firm
      • 8.4.4.2. COVID-19 Pipeline
      • 8.4.4.3. Recent Developments
    • 8.4.5. GlaxoSmithKline (GSK)
      • 8.4.5.1. About the Firm
      • 8.4.5.2. COVID-19 Pipeline
      • 8.4.5.3. Recent Developments
    • 8.4.6. Sanofi S.A.
      • 8.4.6.1. About the Firm
      • 8.4.6.2. COVID-19 Pipeline
      • 8.4.6.3. Recent Developments
    • 8.4.7. Johnson & Johnson
      • 8.4.7.1. About the Firm
      • 8.4.7.2. COVID-19 Pipeline
      • 8.4.7.3. Recent Developments
  • 8.5. Immunotherapy Firms
    • 8.5.1. Sorrento Therapeutics, Inc.
      • 8.5.1.1. About the Firm
      • 8.5.1.2. COVID-19 Pipeline
      • 8.5.1.3. Recent Developments
    • 8.5.2. Astrazeneca Plc
      • 8.5.2.1. About the Firm
      • 8.5.2.2. COVID-19 Pipeline
      • 8.5.2.3. Recent Developments
    • 8.5.3. Pfizer, Inc.
      • 8.5.3.1. About the Firm
      • 8.5.3.2. COVID-19 Pipeline
      • 8.5.3.3. Recent Developments
    • 8.5.4. Cti Biopharma Corporation
      • 8.5.4.1. About the Firm
      • 8.5.4.2. COVID-19 Pipeline
      • 8.5.4.3. Recent Developments
    • 8.5.5. Oncoimmune, Inc.
      • 8.5.5.1. About the Firm
      • 8.5.5.2. COVID-19 Pipeline
      • 8.5.5.3. Recent Developments
  • 8.6. Cell-Based Therapy
    • 8.6.1. Athersys, Inc.
      • 8.6.1.1. About the Firm
      • 8.6.1.2. COVID-19 Pipeline
      • 8.6.1.3. Recent Developments
    • 8.6.2. Cellularity, Inc.
      • 8.6.2.1. About the Firm
      • 8.6.2.2. COVID-19 Pipeline
      • 8.6.2.3. Recent Developments
    • 8.6.3. Pluristem Therapeutics, Inc.
      • 8.6.3.1. About the Firm
      • 8.6.3.2. COVID-19 Pipeline
      • 8.6.3.3. Recent Developments
  • 8.7. Plasma Therapy
    • 8.7.1. Takeda Pharmaceutical Company Ltd
      • 8.7.1.1. About the Firm
      • 8.7.1.2. COVID-19 Pipeline
      • 8.7.1.3. Recent Developments

List of Tables

  • Table 1 Health & Life Sciences Market Opportunity Assessment Post COVID-19, by Product Type, 2019-2025 ($Million)
  • Table 2 Industry Trend & Impact Analysis on Healthcare Sub-Sectors Post COVID-19
  • Table 3 Diagnostics Market Opportunity for COVID-19, by Product Type, 2019-2025 ($Million)
  • Table 4 Diagnostics Market Opportunity for COVID-19, by Geography, 2019-2025 ($Million)
  • Table 5 PCR Cycle and Corresponding No. of Target Copies Produced
  • Table 6 PCR Testing Market Opportunity for COVID-19, by Geography, 2019-2025 ($Million)
  • Table 7 Antibody Testing Market Opportunity Assessment for COVID-19, by Geography, 2019-2025 ($Million)
  • Table 8 Therapy Market Opportunity Assessment for COVID-19, by Product Type, 2019-2025 ($Million)
  • Table 9 Therapy Market Opportunity Assessment for COVID-19, by Geography, 2021-2025 ($Million)
  • Table 10 Key Vaccine Pipeline For COVID-19 (Non-Exhaustive, As of May 05, 2020)
  • Table 11 Vaccines Market Opportunity for COVID-19, by Geography, 2021-2025 ($Million)
  • Table 12 Immunotherapy Pipeline For COVID-19 (Non-Exhaustive, As of May 05, 2020)
  • Table 13 Immunotherapy Market Opportunity for COVID-19, by Geography, 2021-2025 ($Million)
  • Table 14 Antiviral Pipeline For COVID-19 (Non-Exhaustive, As of May 05, 2020)
  • Table 15 Antiviral Market Opportunity for Covid-19, by Geography, 2021-2025 ($Million)
  • Table 16 Cell-Based Therapy Pipeline for COVID-19 (Non-Exhaustive, As of May 05, 2020)
  • Table 17 Cell Based Therapy Market Opportunity for COVID-19, by Geography, 2021-2025 ($Million)
  • Table 18 Plasma Therapies in Pipeline for COVID-19
  • Table 19 COVID-19 Devices Platforms in Pipeline
  • Table 20 Other Therapies Market Opportunity for COVID-19, by Geography, 2021-2025 ($Million)
  • Table 21 Life Sciences Products Market for COVID-19, by Geography, 2019-2025 ($Million)
  • Table 22 COVID-19 Treatment Investments, by BARDA (U.S.)
  • Table 23 North America: COVID-19 Health & Life Sciences Market Opportunity, 2019-2025 ($Million)
  • Table 24 North America: Diagnostics Market Opportunity for COVID-19, 2019-2025 ($Million)
  • Table 25 North America: Therapy Market Opportunity for COVID-19, by Product Type, 2021-2025 ($Million)
  • Table 26 Key Economic Indicators: Europe (2019 - 2021)
  • Table 27 Europe: Health & Life Sciences Market Opportunity for COVID-19, 2019-2025 ($Million)
  • Table 28 Europe: COVID-19 Diagnostics Market Opportunity, 2019-2025 ($Million)
  • Table 29 Europe: Therapy Market Opportunity for COVID-19, by Product Type, 2021-2025 ($Million)
  • Table 30 Key Economic Indicators: Asia (2019 - 2021)
  • Table 31 APAC: Health & Life Sciences Market Opportunity for COVID-19, 2019-2025 ($Million)
  • Table 32 APAC: Diagnostics Market Opportunity for COVID-19, 2019-2025 ($Million)
  • Table 33 APAC: Therapy Market Opportunity for COVID-19, by Product Type, 2021-2025 ($Million)
  • Table 34 RoW: Health & Life Sciences Market Opportunity for COVID-19, 2019-2025 ($Million)
  • Table 35 RoW: Diagnostics Market Opportunity for COVID-19, 2019-2025 ($Million)
  • Table 36 RoW: Therapy Market Opportunity for COVID-19, by Product Type, 2021-2025 ($Million)

List of Figures

  • Figure 1 Research Methodology
  • Figure 2 Market Size Estimation Methodology: Bottom-Up Approach
  • Figure 3 Market Size Estimation Methodology: Top-Down Approach
  • Figure 4 Research Design
  • Figure 5 Data Triangulation Methodology
  • Figure 6 Global Coronavirus Cases, As of 15 May 2020
  • Figure 7 GDP Trend Across the U.S., U.K., Germany, China, and India (2019, 2020 (F), and 2021 (F))
  • Figure 8 COVID-19 Treatment Pipeline, by Development Stage (As of May 2020)
  • Figure 9 Life Sciences Market Segmentation Impacted by Covid-19
  • Figure 10 COVID-19 Treatment Pipeline in Development, by type and Development Stage
  • Figure 11 Vaccine Pipeline, by Category & Development Stage
  • Figure 12 Immunotherapy / Antibodies Pipeline, by Development Stage (As of May 2020)
  • Figure 13 Antiviral Pipeline, by Development Stage (As of May 2020)
  • Figure 14 Cell-Based Therapy Pipeline, by Development Stage (As of May 2020)
  • Figure 15 Key Economic Indicators: U.S. (2018 To April 2020 & Forecast to 2021)
  • Figure 16 Key Growth Strategies, by Development & by Company, Feb - May 2020
  • Figure 17 Key Firms Active in COVID-19 Product Development